The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.

ABSTRACT: The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to important improvements in patient outcomes. However, it is still necessary to increase individualisation of treatments based on tumour genetic profiles to optimise efficacy, while minimising toxicity. As such, there is currently great focus on the discovery and validation of further biomarkers in mCRC, with many new potential prognostic and predictive markers being identified alongside developments in patient molecular profiling technologies. Here, we review data for validated and emerging biomarkers impacting treatment strategies in mCRC. We completed a structured literature search of the PubMed database to identify relevant publications, limiting for English-language publications published between 1 Jan

SUBMITTER: Taieb J 

PROVIDER: S-EPMC6728290 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature